Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Oxxon Therapeutics, Inc.
New patents covering PrimeBoost platform and immunotherapy products announced
November 4th, 2005
Oxxon Therapeutics, Inc., (Oxxon) announced the addition of two new patents to its growing portfolio. These patents contain claims broadly covering aspects of Oxxon's PrimeBoost platform and immunotherapy products. Oxxon's patent estate currently includes the rights to 28 patent families, resulting in over 200 issued patents or patent applications. European patent EP1214416 B1 describes the use of a replication-deficient adenoviral vector to boost a CD8+ T cell immune response following prior administration of a nonadenoviral priming agent where both the prime and the boost encode the same disease-related antigens. PrimeBoost involving adenoviral...
Source: Biotech Law Weekly (2005-11-04)
|
